Foghorn Therapeutics continues advancing its proprietary chromatin-targeting platform with its lead clinical candidate FHD-909 in Phase 1 trials, supported by strategic collaboration with Eli Lilly. The company’s operating losses narrowed slightly in 2025 compared to 2024, reflecting a gradual ramp in partnered programs and platform development alongside non-cash asset impairments and lease restructuring costs. While no product sales revenues have yet emerged, deferred collaboration revenue provides some near-term financial cushioning, complemented by over $158 million in cash and securities as of the end of 2025. Despite improving operating cash flow trends, the company remains dependent on external capital markets for funding its pipeline expansion and commercialization readiness.